key: cord-0876527-tvql4nfr
authors: Siavashpour, Zahra; Goharpey, Neda; Mobasheri, Mosayyeb
title: Radiotherapy based management during Covid-19 pandemic – A systematic review of presented consensus and guidelines
date: 2021-06-30
journal: Crit Rev Oncol Hematol
DOI: 10.1016/j.critrevonc.2021.103402
sha: 704d38ad4479c81f3b18e54c263f492a03f8d21c
doc_id: 876527
cord_uid: tvql4nfr

Treatment management of cancer patients in the radiation oncology departments during the current COVID-19 pandemic is challenging. A systematic review of published consensus/guidelines on the role of radiotherapy prioritization, suggested treatment protocols, and set up management was undertaken based on the PRISMA protocol and through PubMed/PMC, Scopus, Google Scholar, Web of Science databases until 01/20/2021. One hundred and sixty-eight publications or regional consensus were included. Summary of recommendations contained: (1) using hypo-fractionated (Hypo-F) regimens for therapeutic/palliative indications, (2) delaying radiotherapy for several weeks or until pandemic over, (3) omitting radiotherapy by replacement of alternative therapies or active surveillance, (4) applying safer patients' setup and preparation protocols, (5) developing telemedicine/telehealth service. To conclude, it is essential to carefully weigh the risk of exposure to COVID-19 infection and the benefit of treating cancer patients during the pandemic. Trying to have a global guideline facing this or any other probable crisis is crucial for health care service.

The outbreak of coronavirus 2 (COVID-19) is a severe acute respiratory syndrome caused by severe acute respiratory syndrome-related coronavirus-2 (SARS-COV-2). The virus has impacted ordinary everyday life and medical approaches worldwide since about December 2019.

Meanwhile, vulnerable patients such as cancerous ones are at substantial risk and need meticulous care to reduce and avoid all the possibilities of contracting the infection. Since the spread of COVID-19 is a severe and long-lasting catastrophe, termination or delay of treatment may jeopardize patient care and health. The radiation oncology centers are endeavoring to present guidelines on coping with this crisis.

There were two severe acute respiratory syndrome-related coronaviruses (SARS-CoV) and middle east respiratory syndrome-related coronavirus (MERS-CoV) in the 2002 and 2012 outbreak before this current pandemic, respectively [1, 2] . However, the SARS outbreak has been controlled, with no human infection reported since 2003, but MERS' small epidemics continue to be notified [2] . World health organization indicated the initial diagnostic symptoms of this public health emergency as fever and flu-like symptoms and/or breathing difficulty with pulmonary ground-glass opacity (GGO) appearance in the computed tomography (CT) images [3] .

This rapidly expanding pandemic has impacted all daily life areas, especially the clinical routines of other life-threatening diseases such as cancer and its care in radiotherapy departments. Before the pandemic era, the radiotherapy area was categorized based on the risk of radiation exposure and contamination to controlled and uncontrolled areas [4] . However, this pandemic adds other categorization based on the risk of viral infection. Many recommendations were presented by categorizing the treatment department area, room cleaning, sanitization, or disinfection protocols, staff preparation such as having a different level of protective clothing, protocols on setting treatment appointment time for the suspicious or high-risk patients, and urgent event handling [5, 6] .

Immunosuppression in cancer patients makes them more fragile during this crisis, and their treatment has been faced with a severe challenge. As the pandemic becomes more widespread, the population concurrently challenged by cancer and corona will increase across the world J o u r n a l P r e -p r o o f Published data were considered and presented in this review, and therefore no approval of a research ethics committee was sought.

Eventually, considering the explained search, extraction strategy, and inclusion/exclusion criteria crisis. Recommendations support implementing standard/hypo-fractionation radiotherapy regimens, considering omission of radiotherapy for some cases with a high risk of coronavirus infection, and implementing alternatives to the previous patient's preparation/fixation techniques.

Moreover, there was consensus to delay radiotherapy/chemoradiation therapy for those with lesser priority, such as the elderly or fragile case. All of the included recommendations, guidelines, and consensuses are presented in tables 1-4. As shown, the number of guidelines and consensus is almost related to the frequency of cancer type with radiotherapy indication as one of the treatment strategies. For instance, breast, gynecological, and prostate cancer include more than 32% of all diagnosed cancer type. About 23% of all cancer patients who need to receive radiotherapy also have one of these three malignancies around the world [23] .

Numerous recommendations were consistently published to guide radiation oncologists in the era of the COVID-19 crisis. In the beginning, the radiotherapy of some cases was postponed; however, the pandemic has been taking an unexpectedly long time. Therefore, patient selection and prioritization protocols proposed alternative treatments and modification of delivery techniques [13] . Making proper treatment comments require weighing the risk of infection J o u r n a l P r e -p r o o f exposure and the benefit of treatment in a careful manner. A comprehensive review was done to extract the essential recommendations and consensus for radiotherapy during the current pandemic. Figure 1 summarized the results of the review based on the PRISMA protocol. Figure 2 indicates the distribution of papers versus the considered disease site in the coronavirus outbreak. As illustrated, the published recommendations' rate matches the frequency of the most common cancer type worldwide. As presented in this figure, about 24 % of the recommendations were related to the radiotherapy of breast and prostate malignancies. However, based on a recent meta-analysis, most death rates between COVID-19 infected cancer patients were associated with hematological malignancies followed by lung. The higher degree of immunosuppression utilized in treating patients with hematological malignancies was known as the reason for this significant death rate [185] . Previous studies did not indicate any apparent connection between any anticancer treatment modality and the chance of COVID-19 mortality, while the higher intubation and fatality rate of cancer patients was reported [8, 185] . (DIRAC) database [186] . Therefore, many centers cannot technically apply some of these recommendations, such as hypo-fractionated and short-course radiotherapy techniques. According to Figure 3 , developing countries published less guidance to face this scope. They rarely addressed their consensus, which may be due to fewer radiotherapy centers/high-tech equipment comparing to the developed ones. Eventually, some of these prescribed consensuses or even international recommendations do not fit the facilities, equipment, and staff knowledge across the whole RT centers. Considering the availability of dedicated high-tech equipment and J o u r n a l P r e -p r o o f human resources and tailoring COVID-19 pandemic management strategies to the regional context was not only recommended but also seemed mandatory [20] .

Tables 1 and 2 summarizes the prioritization strategies of common cancer types to mitigate the demand of EBRT and brachytherapy during this crisis retrospectively. Some authors categorized the priority scale in three levels of omission, delayed, and continuing the irradiation. Using the short-course irradiation or hypo-fractionated radiotherapy (Hypo-F RT) over normal fractionation is the most frequent and preferred standard of care for radiotherapy during the pandemic.

Recommendations support the utility of active surveillance in low-risk tumors, which permitted to defer the treatment based on the disease biology and pathology, for several months or until an expected fall or management of COVID-19 pandemic. Taking into account that deferred therapy should not lead to detrimental impacts on treatment consequences. Moreover, it suggested avoiding radiotherapy for patients with poor prognostic tumors in early-stages (e.g., Hodgkin's Lymphoma) and low-risk (e.g., postoperative radiotherapy for thymoma) disease. It was recommended to omit the treatment of palliative setting as long as the patient symptom can be under control by adopting alternative approaches, elderly patients with severe health circumstances, benign disease (e.g., keloids), and boost whenever possible [15, 26, 187] . These approaches have been summarized in Table 1 .

Based on the suggested prioritizations (Table 1) , radiation treatment should maintain and continue according to the pre-pandemic schedule for patients underway of therapy unless the COVID-19 virus infects them. The treatment should sustain for urgent issues, where there is no alternative modality to radiation therapy and those with symptomatic metastatic disease with a life expectancy of at least 3-6 months. Preoperative RT has also been reported to buy some time for postponing surgery [16] . Deferral treatment commencement for patients with a potentially promptly growing tumor and curative intention can jeopardize outcomes and should be classified as a high priority level [115] .

Based on the published references (Table 1 and 2), some cases including high-or intermediategrade cancer, frail patients who are not eligible for surgery, hormone-sensitive cancers (e.g., breast and prostate cases), malignancies in locally advanced stages (e.g., breast, lung, cervix locally advanced cancers) should treat as the standard of care. Emergency cases (known as the urgent category) such as superior vena cava syndrome (SVCO), uncontrolled pain or bleeding, occlusion, and spinal cord compression are recommended for radiotherapy continuation with high priority [188, 189] . Table 3 summarized the department's consensus for radiotherapy candidates during pandemic and indications of the feasible Hypo-F RT and short-course treatment regimens. Extending the use of an evidence-based Hypo-F RT schedule or simultaneous integrated boost (SIB) (e.g., for prostate, breast, and head and neck cases) and short-course radiation therapy (e.g., for rectal cancer) were recommended frequently. There are also other classifications based on (1) the urgent/critical and non-urgent/non-critical treatment indication, (2) high-risk/ high-grade pathological malignancy stages, (3) degree of cancer cell proliferation, (4) the feasibility of treatment options during the pandemic, and (5) patient's performance status [15, 25, 26, 190] .

Presented consensuses and recommendations of Tables 1-3 can be summarized based on the cancer type as follow:

In glioblastoma multiform (GBM) cases, age and karnofsky performance status (KPS) of patients introduced as the determining factors in choosing radiotherapy schedule and fractionation (e.g. Gy / 5 frs) [24] . Continuing treatment was generally recommended for high-grade glioma cases with not poor KPS. For example, Hypo-F RT can be considered where there is not any probability of compromising outcome (e.g., for patients with brain metastases or O 6methylguanine DNA methyltransferase (MGMT) promoter-unmethylated glioblastoma) based on the ESMO recommendation to reduce hospital visits [191] . Stereotactic radiosurgery (SRS) was suggested for solitary or limited brain metastases (up to four lesions with less than 4 cm J o u r n a l P r e -p r o o f maximum size) with good KPS patients. SRS with 15-24 Gy can be prescribed based on the maximum lesion size. Whole-brain radiotherapy (WBRT) is still introduced as the standard of care for more or/and larger brain metastatic lesions (Tables 1-3 ) [192] .

For head and neck cancer patients, all indications for continuing the combined chemo-RT must be preserved following the acceptable delay time between diagnosis and RT (i.e., ≤ four weeks) or between surgery and RT (i.e., 6 to 8 weeks) [193] . Radiotherapy omission was allowed just for benign or low-risk slow-growing lesions (Table 1) . Delaying radiotherapy is also permitted not more than 4-6 weeks for COVID-19 positive cases or in cases such as melanomas, as indicated in Table 1 in detail. RT fractionation must be optimized using Hypo-F RT, simultaneous integrated boost (SIB), accelerated RT scheduling (6 frs / week), or SBRT techniques. Strong agreement was reported following ASTRO-ESTRO consensus to shift from the standard approach (2-2.4 Gy / fr) to the Hypo-F regimen (2.21-3.2 Gy / fr) or Ultra-Hypo-F RT (e.g., 8 Gy / 1fr or 20 Gy / 4 fr) for palliative cases, during the breakdowns and shortage of RT capacities. However, in these cases, concomitant chemotherapy was restricted to the RT regimen with a prescribed dose of less than 2.4 Gy / fr [194] . It is recommended to continue brachytherapy of oral tongue cases with high local recurrence probability and SCC of the lip, oral mucosa, and nasal region. Switching to EBRT is preferred for COVID-19 positive cases, also patients and caregivers with a higher risk of infection (Table 2) .

Based on a previous review, the RT of breast cancer in cases with locally advanced and inflammatory, residual positive lymph node (N2), recurrent, triple-negative node-positive, and extensive lymph vascular invasion categorized with high priority indication [195] . The most frequent thresholds for age and maximum tumor size were 65 years old and 2.5-3 cm, respectively. Standard Hypo-F RT (i.e., 40 Gy / 15 frs), the routine schedule for breast irradiation, is the most highlighted proposed technique during the pandemic. However, using FAST (26 Gy in 5 fractions once weekly) and FAST-Forward (26 Gy in 5 fractions daily) regimens were also emphasized for a patient requiring breast or partial breast EBRT (Table 1 and 3) and a center that dedicated with IGRT. The omission of radiotherapy was proposed for lowgrade elderly patients (or post-menopausal cases) with negative lymph node involvement, ER-J o u r n a l P r e -p r o o f positive and HER2-negative case for whom adjuvant endocrine therapy was planned (Table 1) .

Switching to EBRT instead of BT is highly recommended due to the additional demand for resources and hospitals. However, when BT is feasible, applying HDR accelerated partial breast irradiation (APBI) or LDR interstitial brachytherapy (LDR) technique using a single applicator or needle entry was proposed for early-stage disease. It allowed a maximum delay of 12 weeks for patients' RT of ductal carcinoma in situ (DCIS) cases with high RT indication (e.g., ERnegative with positive surgical margin).

Almost all related kinds of literature recommended continuing RT for non-small cell lung cancer (NSCLC), limited-stage of small cell lung cancer (LS-SCLC), or palliative setting (Table 1) during the pandemic. However, they proposed to hold off RT for the extensive-stage (ES-SCLC).

Delaying the prophylactic cranial irradiation (PCI) of SCLC with both limited and extensive disease was highly recommended in the COVID-19 pandemic setting [196] . The stereotactic body radiotherapy (SBRT) technique with a limited fraction number is the ideal RT option during the pandemic era. For instance, the fractionation suggested for the peripheral and central tumors of NSCLC was 54 Gy / 3 frs and 50 Gy / 5 frs, respectively. Besides, for limited-stage and extensive SCLC stage, 40 Gy / 15 frs and 25 Gy / 5 frs for radical and consolidation radiotherapy, and 25 Gy / 10 frs for PCI, respectively [73] .

Continuing CRT or neoadjuvant RT for esophageal cancer treatment using the Hypo-F RT regimen was frequently recommended (e.g., 50 Gy / 16 frs for tumors up to 5 cm, 55 Gy / 10 frs for tumors up to 10 cm in length, and 40 Gy/15 frs for neoadjuvant Hypo-F dCRT) [85] . Surgery can be postponed up to 3 months for these cases [193] . Tumor length was defined as a restricting factor for dose per radiotherapy fraction (Table 1 and 3). SBRT (e.g., 24 -60 Gy /1-5 frs), proton therapy, or systematic RT was suggested for the liver malignancies based on the cancer stage [160] . For locally advanced pancreatic cancer continuing with Hypo-F RT with/without SBRT technique is recommended for both unresected (single fraction SBRT (8-10 Gy) for palliation) and resected cases (SBRT: 30-33 Gy / 5 frs and without SBRT: 25 Gy / 5 frs, or 30 Gy /10 frs) [86] . For operable cholangiocarcinoma, surgery can be the J o u r n a l P r e -p r o o f 13 option of cancer management. Avoiding BT was suggested for patients with esophageal-and cholangial-carcinoma until the pandemic and the risk of virus transmission reduces.

For locally advanced rectal cancer (LARC), delaying radiotherapy is not recommended to decrease the recurrence rate and increase anal sphincter preservation probability [94] . However, neoadjuvant short-course radiation therapy (SCRT) (i.e., 25 Gy in 5 frs) with postponed surgery (up to three months) for the intermediate-to high-risk patients can be an optimum choice based on the recommendations of the pandemic setting to decrease the frequency and duration of the patients' exposure. However, distance from the mesorectal fascia (MRF-D) is considered a restricting factor for SCRT selection. Long-course chemoradiotherapy (LCCRT) (i.e., 45-54 Gy in 25-30 frs) was suggested for patients with MRF-D ≤ 2 mm to safely delay the surgery and improve the chance of clinical response. Adjuvant RT can be omitted or postponed for earlystage and low-risk cases [196] . Delaying or omitting rectal BT is recommended for all patients except for unresectable lesions, frail elderly, or medically inoperable ones [94, 132] . It was suggested to continue the anal cancer radiotherapy by Hypo-F RT regimen (e.g., 30 Gy / 10-15 frs) or following the standard treatment. However, switching from BT to EBRT or IORT was suggested in these cases (Tables 1-3) .

Delaying or omitting surgery for muscle-invasive bladder cancer (MIBC) patients and choosing treatment options like RT and chemotherapy may be suboptimal. However, in the COVID-19 pandemic, this delay has been avoidable due to operating room closure and saturation of ICU beds [197] . Therefore, some recommendations were proposed for treating these patients using RT even by curative or palliative indication. Hypo-F RT was the dominant suggested regimen by, for example, 55 Gy / 20 frs and 21 Gy / 3 frs for curative and palliative purposes, respectively (Table 1) . SIB technique can also be applied for the unresected cases. It's better to continue RT, but with a Hypo-F regimen (e.g., 24 Gy / 1-4 frs) for unresectable or medically inoperable renal cell carcinoma (RCC) cases.

In prostate cancer, EBRT omission and active surveillance (AS) were recommended for very low-, low-, and intermediate-to-low-risk cases during the pandemic. 3-6 months delaying radiotherapy and using AS, ADT, or hormonal deprivation can be chosen for low risk, intermediate-to-high, high-risk, or localized prostate cancer in a post-operation setting. It is J o u r n a l P r e -p r o o f recommended to continue radiotherapy for high-risk and advanced cases with curative intent.

The Hypo-F RT regimen is highly preferred (Table 1 and 3) . This irradiation regimen (e.g., 36

Gy / 6 frs) is also suggested for oligometastatic disease [193] . Radiotherapy omission of lowstage seminoma was also preferred. Shortening the BT fractionation of intermediate-and highrisk prostate cancer (e.g., 15 in one fraction) or ultimately shifting to the EBRT to reduce the risk of patient exposure to the infection is proposed during the pandemic.

In gynecological cancer, adjuvant treatment after surgery with curative intent has a high-priority for radiotherapy [198] . For example, not postponing EBRT or BT was highly suggested for locally advanced cervical cancer (Tables 1 and 2 ). In invasive uterine cervix carcinoma, it was proven to have lower tumor control and higher recurrence risk when the overall treatment time (OTT) exceed more than seven weeks, especially for squamous cell carcinoma (SCC). Tanderup et al. suggested an additional 5 Gy dose to the high-risk CTV (CTVHR) to compensate for the local control loss if the OTT increases from one week to more than seven weeks [199] . Therefore, the proposed consensus tried to align these principles and keep the OTT less as possible, even by hypo-fractionated brachytherapy (Table 3) . Continuing EBRT in advanced stages or palliative situation of endometrial, ovarian, and vulvar cancer was also recommended during this crisis. Postponing BT for intermediate-risk gynecological malignancies except for cervical cancer or COVID-19 positive patients is also proposed ( Table 2) .

Preoperative RT of soft tissue sarcoma (STS) is not generally accepted due to the higher risk of wound complications after radiotherapy. However, there are also some benefits for this neoadjuvant RT, such as the lower risk of tumor cell seeding during operation, lesser organs at risk exposure during radiotherapy. In the pandemic, two more benefits of decreasing the OTT and the risk of exposure to virus infection were added to this neoadjuvant treatment, especially for large border-line resectable sarcomas using the Hypo-F regimen (e.g., 28 Gy / 8 frs or 25 Gy / 5 frs) [170] . SBRT is a good treatment option for these patients with unresectable or lung metastases from sarcoma. Preoperative RT for Ewing's sarcoma cases can be an option where surgery is not feasible or suitable [200] . In specialized and dedicated centers, HDR-BT can be employed for soft tissue cases such as rhabdomyosarcoma.

J o u r n a l P r e -p r o o f Pediatric The oncologists recommend following the standard treatment for pediatrics as long as the radiotherapy has the most efficient clinical consequence [115] . Radiotherapy omission was just recommended for low-grade cases or where the palliative care is intended based on the pediatric part of Tables 1 and 2. Five priority levels were defined for continuing radiotherapy of pediatrics, dedicating higher RT priority to the medulloblastoma, high-grade ependymoma, retinoblastoma cases, and lower priority to the low-grade glioma and meningioma cases (Table   1 ). Continuing the brachytherapy of pediatric patients has also been emphasized in the pandemic period ( Table 2) .

For aggressive disease, T-Cell and high-grade lymphomas, or for symptomatic patients continuing radiotherapy should be selected. However, RT was recommended for even earlystage Hodgkin lymphoma (HL) [201] . Radiotherapy can be ignored in old patients with lowgrade lymphomas or when good results were obtained after surgery or chemotherapy (Table 1) .

Definitive RT of melanoma, unresectable SCC and basal cell carcinoma (BCC), and rare cases of Merkel cell carcinoma (MCC) were suggested during the pandemic (Table 1) . However, adjuvant RT's omission can be chosen for BCC, melanoma, and SCC with low relapse risk and when the limited benefit is expected. Delaying radiotherapy up to 3 months was proposed for non-prompt growing disease or rare skin pathologies, which were incompletely excised.

Radiotherapy omission and switching to the supportive care accomplished with medical therapies were proposed for patients with short life expectancy (days to few weeks) during the coronavirus pandemic setting. These patients are usually in critical conditions that need supportive immobilization or even getting help from palliative sedation to reach stable positioning during treatment, which requires a higher number of caregivers with a higher risk of infection [33] . For the other cases, prioritization was performed to ease patient selection for palliative RT. As mentioned, patients with neurological or airway compromise or tumor bleeding J o u r n a l P r e -p r o o f belong to the highest priority (Table 1 and 2). Using Hypo-F RT with a short number of fractions reaches desirable outcomes for patients requiring palliation for oncologic emergencies without compromising care. For example, 20 Gy / 5 frs for brain metastasis (urgent indications), 8Gy/ 1fr for spinal cord compression and bone metastasis, 14.8 Gy / 4 frs twice daily or 20 Gy / 5 frs tumor bleeding, and 17 Gy / 2 weekly fractions of 20 Gy / 5 daily fractions for SVC or airway obstruction (Table 3 ) [131] . Using SBRT or frameless SRS was also suggested for these patients where these radiotherapy techniques are feasible. Avoiding palliative BT was proposed to minimize coronavirus infection risk [135] .

For the benign disease, delay of radiotherapy was proposed. BT has reasonable local control for keloid cases. However, during the pandemic setting, the risk-benefit analysis leads to BT omission and switching to EBRT, such as treatment with the electron beam.

Selecting the best techniques to reduce the organs at risk (OARs) doses of each patient relies highly on the center's available equipment, staff's experience, patient's anatomy, and disease site.

However, another aspect added to the previous criteria by selecting the best technique for patient positioning and monitoring the simulation and RT delivery during the pandemic. By considering all these aspects and patient benefits, the radiotherapy can be performed by some delivery techniques for better patient management and positioning. Table 4 summarized some of these techniques recently addressed by radiotherapy professionals in the pre/post-pandemic era.

For instance, in breast cancer, RT delivery techniques such as deep inspiration breath-hold (DIBH) can be performed voluntarily, with moderate or active breathing control/coordinator (ABC) equipment. ABC's utility is clinically necessary to control the dose of lung and heart (for left breast cases). It is also applied for gastrointestinal, thoracic, or pediatric patients if using abdominal compression or free-breathing leads to severe and unacceptable toxicity without reaching the normal tissue safety objectives [15] . CBCT or prone positioning can also be used, mostly in case of reducing the delivered dose of lung and heart, and suggested as an alternative J o u r n a l P r e -p r o o f to reduce the infection risk during the pandemic situation by the majority of departments based on Table 4 [202, 203] . However, daily CBCT can prolong treatment time and increase staff and exposure risk in other points of view. Therefore, it is also recommended to pay attention to this note-getting weekly CBCT or even the use of orthogonal films [14] .

It can be more useful to apply BBD (Belly Board device) for pelvic malignancies whenever the small bowel dose could be a restrictive factor for target dose escalation in clinical routine [204] .

For lung cancer, the supine position is superior to prone orientation by mitigating the target margins [205] . Nevertheless, using spirometry analysis for respiratory gating of lung cancers was also abandoned and replaced by 4D scanners usage to high-risk components management; it avoids the risk of contamination spread from breathing filters and droplet precautions (Table 4 ) [148] .

It was also suggested to apply a chin rest for a slit lamp exam or chin strap, rather than the bite block during the proton therapy of uveal melanoma by the Particle Therapy Co-Operative Group (PTCOG). It can decrease the salivary fluid and maintain the positioning and reproducibility accuracy in parallel to care about the cleaning condition [183] . However, it is more time consuming to use prone positioning than routines supine or acquire daily CBCT rather than using ABC for each case. However, getting daily CBCT of patients can help detect COVID-19 cases caused lung infection in asymptomatic or mildly symptomatic (Table 4 ) [184] . It is essential to distinguish between radiation-related pneumonitis and ground-glass opacity from pulmonary symptoms of COVID-19 on chest CT images of patients undergoing chest radiotherapy [206] .

Eventually, besides choosing the best alternative procedures, shortening treatment time is dramatically crucial to alleviate droplet transmission risk among patients during the pandemic.

Upper airway procedures should be performed using personal protective equipment (PPE) such as wearing an N95 facemask, eye shield, and gloves based on the American Academy of Otolaryngology recommendation. On the other hand, all head and neck cancer cases need a thermoplastic mask during the simulation and treatment steps. Some of these cases also require a tongue blade, individualized mouth prosthesis, or bite blocks. Using these additional setup helpers caused controversy by having PPEs during the RT steps. Therefore, the centers suggested their novel approaches for making and forming the masks and tongue depressors facing this challenge during the pandemic [177, 207] . 

For patients with an indication of definitive CRT (dCRT), robust processes should be obeyed to ensure that their radiotherapy can uninterruptedly continue their treatment even with approved COVID-19 infection (Table 1) [208] . Patients with spinal cord compression, bleeding, or SVCO syndrome are such cases to follow the routines.

It was suggested to dedicate a treatment machine to these cases or treating them at the end of the day by obeying post-treatment cleaning protocols [85] . It was suggested to postpone RT for head and neck, lung, gynecological cancer cases for a few weeks until resolving symptoms and subsiding inflammation. Using prone positioning instead of the supine one with the DIBH technique was also a reported consensus for COVID-19 positive breast cancer cases [148] .

Switching to EBRT (with standard or hypo-fractionated regimen) was proposed as an alternative for continuing the treatment of COVD-19 positive cancer patients with BT indication such as GYN or rectal cases [132] .

Hypofractionation is the most reported consensus of RT departments during the COVID-19 pandemic to minimize the risk of cancer patients' contagion without reducing their treatments' effectiveness (Tables 1 and 3 ) [209] . However, there are some doubts about the long-term results and toxicity of the proposed treatment schedule during this pandemic crisis due to the absence of long-term randomized trials in some suggested regimes. Using SCRT for rectal cancer can be named an example, especially for those who suffered from low rectal tumors and bulky ones with a close or positive circumferential residual margin [162] . Definitive Hypo-F RT of inoperable esophageal cancer patients is another example of debate due to the increasing probability of late toxicities [86, 210] . However, the centers accept these risks and mandate Hypo-F short-course radiotherapy to reduce patient infection likelihood with the coronavirus in the pandemic setting [162] . However, in some cases, de-escalation of treatment intensity, such as advanced head and neck cancers, is not as curable as standard care. Consequently, these patients should be discussed and informed about the risk and benefit of choosing Hypo-F and standard fractionated regimens, their frequency of hospital visits, the potential of immunosuppression, and the risk of exposure to coronavirus infection [211] . Furthermore, based on Table 1 and the previous published papers data, there has been a significant omission or reduction and less intensive prescribing of RT strategies for elderly patients during the pandemic [50, 195] . Reducing hospital admission frequency and following the isolation procedures was highly recommended for fragile and low-performance patients.

Based on the recent adaptive recommendations for the older cancer patients, some similar protocols such as breast cancer Hypo-F RT or IORT and avoiding boost for the early stages, rectal cancer SCRT, single-fraction RT for palliative purposes, SRS technique for early nonsmall cell lung cancer (NSCLC), or central nervous system (CNS) metastases [212] . However, RT omission can be justified for frail or older patients due to the reported comorbidity and poor outcome of age and COVID-19 infection [213] .

The relationship between previous suggested OARs dose constraints and the risk of mortality and morbidity was also addressed during the COVID-19 emergency of cancer patients [214] .

These researchers performed a retrospective analysis to determine if the extent of prior lung irradiation can be a risk factor for death due to COVID-19 infection. They concluded that a mean lung dose of 7 Gy and 15 Gy yields a predicted COVID mortality rate of approximately 50% and 75%, respectively [214] . This result can be included in the previous radiobiological consideration in defining the organ at risk dose constraints and revising them, especially during pandemic conditions.

Multiple authors highlighted some issues in anticipating the pandemic's termination in their busy RT departments to incorporate new treatment techniques and management using the crisis experiences. These techniques include Hypo-F RT scheduling, real-time data monitoring by new visualization tools, telemedicine utilization, and remote working [148, 149] .

As mentioned previously, choosing shorter fractionation schedules for palliation and cure is critical to adapt to the regional health system. This technique necessarily needs the use of advanced RT skills and high-tech equipment for imaging, planning, immobilization, and treatment delivery to avoid the increasing of normal tissue toxicity; it also mandates to maintain the equivalent benefit as in conventionally fractionated radiotherapy [20] Therefore, there is still a long way to reach optimum cancer treatment all over the world. It is necessary to renew some emergency national/international protocols parallel to different aspects of RT developments. Overall survival and disease-free survival of various cancer stages have J o u r n a l P r e -p r o o f been updating through the newly published references influenced by the improvements in screening culture, follow-ups, and the mentioned treatment progresses. Hence, it should be frequently renewed the patient prioritizing to receive RT according to anticipated outcomes.

The COVID-19 pandemic challenged healthcare resources by creating an extraordinary struggle.

The oncology community has been suddenly required to protect a group of cancer patients. They are assumed to be susceptible to a potentially fatal infection without threatening cancer treatments. Risk-to-benefit ratios should be considered dealing with quarantine laws, shortages, lockdowns situations, and cancer treatment priorities [12] . At the early of the pandemic, every cancerous patient was assumed to be at higher risk of mortality from COVID-19. This assumption originated from the rapid primary publications, which caused abandonment or delay of some anticancer treatments, particularly for those who were the candidate to receive systemic treatments [12] . Some multi-central studies find no meaningful associations between the COVID-19 mortality with any cancer type and anticancer therapies such as their current radiotherapy, cytotoxic chemotherapy, hormone therapy, or targeted therapy. On the other hand, some recommended treatment protocols or RT fractionation for which the phase III trials were not done or ongoing [26] .

In conclusion, it should be acknowledged that a recent meta-analysis shows cancer patients have higher mortality, although some studies did not show a strong link [8, 9] . Therefore, it is imperative to reconsider and rethink suggested cancer care protocols during the COVID-19 outbreak. It should be discussed to consider the oncological care, individualized risk factor assessment to choose the pre-pandemic standard approach and avoiding definitive and effective treatment strategies or switching to the new therapeutic options based on the pandemic situations.

The authors declare that there is no conflict of interest.

There is no conflict of interest.

There was no funding source for this study.

The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. -Age ≥ 65 years (younger with comorbidities) + invasive breast cancer < 3 cm with clear margins + grade 1/2 + ER+ and HER2-+ node-planned for endocrine therapy -Omit boost or shift to Hypo-F RT (except in patients < 40 years age and whom with a high risk of local recurrence) -Omit nodal RT for Postmenopausal women with T1, grade 1-2, ER+, HER2-a tumor with 1-2 macro metastases requiring WBRT following BCS and sentinel node biopsy Postop RT: for several weeks or even months Adjuvant local RT in early-stage breast cancer: 26 Gy /5 frs over 1 week is non-inferior to 40 Gy / 15 frs over 3 weeks for (UK FAST-forward trial) [63] boost RT in selected patients adjuvant RT: up to 3 months after surgery Hypo-F RT for adjuvant treatment [64] Certain Hypo-F breast RT for 1 week [71] Selected patients: 28.5-6 Gy / 5 frs with DIBH over 1-2 weeks [ Palliative RT (6-8 Gy / 1 fr) [86] Perioperative: neoadjuvant chemotherapy/CRT, adjuvant chemotherapy /CRT Preoperative RT to delay surgery Postoperative RT [14] Non-surgical approach for non-urgent gastrointestinal cancer [30] Adjuvant curative RT [20] cCRT: 40 Gy / 15 frs For tumor 5 cm in length:50 Gy / 16 frs and up to 10 cm 50-55 Gy in 20 frs [33] Postpone RT up to 3 months in indolent disease [37] Gastric Adjuvant curative RT [20] Operable and resected cases: RT may be avoided Palliation: Short fractionation schedules [ Early salvage RT over adjuvant RT after radical Shorter RT regimen (60 Gy / 20 frs or even 5-6 frs in total) [40] All other curative-intent prostate cancers Curative-intent high-grade prostate cancer [15] Low-favorable intermediate-risk Cervical cancer with extreme bleeding [15] All patients with curative intent RT: -Early-stage: definitive RT Pelvic RT remains the selective treatment (Reduction of fraction/preferred IMRT and SIB otherwise conformal RT esp. for node-negative) [105] Pre-invasive, early-stage, locally-advanced disease: Hypo-F RT [106] Reduction of chemotherapy dose, plus RT or RT alone. Intact cervix: -Definitive RT (40 -50 Gy) -IMRT or SBRT boost [14] RT and cCRT (substitute surgery) [ 

Consolidation therapy for high-grade lymphomas Low-grade lymphomas (most patient)

High-grade lymphomas with severe or life-threatening symptoms [15] HL: if RT not available

Peripheral T-Cell Lymphomas (PTCL): aggressive disease [118] Early-stage HL (RT elimination costs of 6-8% disease control) [30] For ≥ 60 yrs: -for the palliative purpose where alternative treatment is available -for localized low-grade lymphomas if completely excised -for localized nodular lymphocyte-predominant HL if completely excised -in consolidation RT for diffuse large B-cell lymphoma/ aggressive NHL for those who have completed a full chemotherapy course with complete remission.

When there is no/little expected adverse effect: -for asymptomatic localized low-grade lymphomas; -for localized nodular lymphocytepredominant HL -in a palliative setting for low-grade lymphomas in stable cases; -for whom develop COVID-19 infection before commencing RT Using alternative Hypo-F RT when RT cannot be omitted or delayed to maintain high cure/palliation rates without excessive toxicity (e.g., For patients with symptomatic sites of disease and Localized aggressive NHL, primary RT alone, and NK-/T-cell lymphoma) [119, 120] In a minority of cases, if alternative treatment options were available Shortening of treatment via Hypo-F RT or limitation of total dose for hematooncological patients: -Painful osteolytic lesion caused by multiple myeloma in non-weight bearing bones after stabilizing surgery: 8Gy/1fr, 20Gy/5frs, 24Gy/8frs, and 30Gy/10frs -Osteolytic lesion of multiple myeloma in weight-bearing bones (e.g., axial skeleton) without surgery: 20Gy/5frs and 24-36Gy/8-12 frs -Diffuse large B-cell lymphoma with the initial abdominal bulky disease after completion of six cycles of R-CHOP a) With no information on PET status: 27-30Gy/9-10 frs b) PET-positive after treatment: 36 Gy/12frs -Early-stage indolent lymphoma in a noncritical location: 4Gy/1fr and 27Gy/9 frs or 4Gy/2 frs [121] High-risk lymphomas [37] Skin Primary and resected skin cancers (if not use short courses and limit radiation to the mucosa)

Unresected SCC/BCC: -Primary tumors < 2 cm: 30 Gy / 5 frs over 2 weeks -Primary tumors > 2 cm: 45 -55 Gy over 3 to 4 weeks, 10 . 2 Gy in 3 frs weekly Resected SCC/BCC: -50 Gy / 4 weeks (2 . 5 Gy / fr) -44 Gy / 10 frs in 4 days a week Melanoma Definitive cases: 35 Gy / 5 frs over a week for < 3 cm 2 Postop: 30 Gy / 5 frs twice a week or every other day [14] CM: -Patients with ≥ T2 disease for three months with negative biopsy margins -T0-T1 disease for three months if no macroscopic residue is detected at biopsy BCC: up to 3 months except for extremely symptomatic patients cSCC: -T1-T2a disease for 2-3 month except for prompt growth or symptomatic/immunosuppressed patients (prioritize patients with ≥ T2b disease) MCC: -Around one month for patients with favorable T1b disease High-risk patients: COVID-19 infection, elderly, and/or weak patients [122] Non-melanoma skin tumors [17] Adjuvant RT for BCC (with limited benefit) Definitive RT including incompletely excised cSCC, MCC, and rare skin pathologies incompletely excised: for 2-3 months

Definitive RT: cSCC, MCC, and rare skin pathologies (modified fractionation) [123] Melanoma ( 

Cord compression, superior vena cava obstruction, life-threatening bleeding: Do not defer until a reasonable alternative (Radical treatment) [51] Painful spine metastasis, Spinal cord compression or spine metastases with the epidural disease, Brain metastases <5 mm, Patients with stable or minimum symptomatic oligo-metastatic disease Cord compression, Symptomatic brain metastases or brain metastases >5 mm, Malignant airways obstruction, SVCO, Severe pain from primary, Heterotopic bone [15] Brain metastases (SRS for good PS/SRS of resection cavity for postop) [25] Painful metastasis, uncomplicated, other systemic options Oligometastatic (e.g., prostate cancer) Painful metastases without impending structural/neurologic compromise Bone metastasis, no fracture, +/-cord compression Bone metastasis, fracture/surgery Postoperative radiotherapy (for pathologic fracture) CNS metastasis from NSCLC needing WBRT Brain metastasis Esophageal bleeding/ dysphagia GBM, poor KPS Head & Neck SVCO Syndrome/Lung cancer Lymphoma, low grade Pelvic/GI bleeding (reduction of fractionation) [26] Prostate cancer patients, breast cancer patients, benign CNS tumor (up to 3 months from diagnosis to treatment) Urgent treatments: -Spinal cord compression, superior vena cava syndrome, life-threatening lower airway obstruction, digestive or respiratory hemorrhage, and life-threatening brain lesion (RT delivered within 24-48 h) Non-urgent treatments: -Painful metastatic bone lesions, lung cancer-causing chest pain or Pancoast syndrome, tumors causing nerve root and soft tissue infiltration, relief of impending airways or bowel obstruction (start of RT within seven days) Elective priority treatments: -Head and neck cancers, rectal and anal cancer, the gastroesophageal junction [27] Palliative non-emergent indications [17] In cases of spinal cord compression, metastatic bone pain irresponsive to other treatments or micro-vascular bleeding: single fraction [6] Palliative intent in asymptomatic or oligosymptomatic patients Spinal cord compression, SVCO, or bleeding in confirmed cases of COVID-19 [59] Symptomatic brain metastases: 20 Gy / 4 -5 frs For COVID-19 patient: Palliative RT for a highly symptomatic patient (life expectancy > 3-6 months) and without any other therapeutic alternative [57] Painful bone metastasis patients (controlled by level 1 to 3 oral analgesics)

Adjuvant bone metastasis RT: MESCC: Adjuvant RT after surgery for 4 to 12 weeks Bone oligometastases and other SBRT indications: for a few weeks, esp. for hormone-sensitive tumors

The omission of whole-brain radiation: multiple brain metastases and limited life-expectancy (<3-6 months)

Single-fraction palliative RT for bone metastases/metastatic spinal cord compression [36] High priority: Spinal cord compression with potential neurological recovery Moderate priority: Palliation of symptoms like hemoptysis in lung cancer [48] Selected palliative treatments [37] High priority: Spinal cord compression, brain metastases, other critical metastatic lesions Low priority: Palliative RT for asymptomatic recurrence not amenable to surgery [111] Pain or bony lesion: 8 Gy / 1 fr; Bleeding: 10 Gy / 1 fr; 20 Gy /5frs (If single fraction not possible, Hypo-F RT) Multiple brain metastases: 20 Gy / 5 frs (in the favorable subgroup) MSCC: 8 Gy / 1fr [84] Symptomatic bone metastases: 8 Gy/1 fr [71] Benign Disease

Benign Disease, Pituitary Adenoma, Fibromatosis Other: Actinic Keratosis, Recurrent/Refractory Fasciitis, other rare benign [26] Benign tumors (schwannomas and asymptomatic meningiomas) [6] Keloid, heterotopic ossification, actinic keratosis [58] Non-malignant indications [17] Benign tumors: RT after 3 months [37] RT 

Early-stage cases: -Use balloon-or multicatheter-based BT instead of EBRT [133] Low-risk cases: Postpone interstitial BT for up to 16-20 weeks for ER+ invasive cases or 12 weeks for DCIS [132] Patients prescribed for definitive or adjuvant therapy: -Shorten BT fractionation schedules Early-stage: -Neoadjuvant endocrine therapy due to delay of surgeries during the crisis; -Adjuvant therapy after BCS -Deem BT as an equivalent option to EBRT -BT for APBI with a single-entry intra-cavitary or multi-catheter interstitial technique after surgery Invasive cases: -Induction of therapy for within 12 weeks after surgery, not more than 20 weeks (BT after BCS) [136] Accelerated partial breast irradiation (Exclusive): -Opt for EBRT according to local facilities [134] Accelerated partial breast irradiation (Exclusive): -Postpone (8-12 weeks) Apply EBRT instead of BT [135] Very Low-, Low-and 

For palliative and post-transplant stenosis: -Avoid BT until the pandemic solves [132] Gastrointestinal Esophageal Palliation with symptoms: -Continue BT [133] -Palliative and re-irradiation: -Avoid BT until the pandemic solves [132] BT with Endoscopic procedures (esophagus or bronchus): -Omit and consider EBRT options [134] Hepato-biliary Avoid delaying the treatment using BT [133] Hilar Cholangiocarcinoma cases with COVID-19+ during RT: -Continue EBRT rather than BT boost Palliative unresectable malignant biliary obstruction or hepatocellular carcinoma cases (not for the transplant) and metastatic lesions: -Avert BT until pandemic solves [132] Rectal For COVID-19+ patients: -Hypo-F-EBRT rather than BT boost Preoperative or definitive postpone brachytherapy until pandemic solves (Hypo-F RT) [132] After SCRT: -For Unresectable, Medically inoperable, or Frail elderly cases: 10-20 Gy in 2-4 frs [94] Anal -Switch interstitial BT to EBRT -Switch to IORT if facilities are available [135] Genitourinary Prostate

Continue [134] If BT can be employed as a sole modality for penile region cases [135] Low-risk patient: -Delay BT up to 3-6 months

High-risk patients: -BT as a boost, avoiding any deferent: 13 . 5 Gy /2 frs of BT alone or 15 Gy/1 fr as EBRT boost [133] For COVID-19+ patients during EBRT: -Interrupt treatment to let recovery up to 10-14 days before restarting/plan for BT For COVID-19+ patients after 1st session of HDR, defer 2nd fraction to allow recovery up to10-14 days

High-risk cases: -Delay all monotherapy BT High-risk cases: -Defer starting EBRT and keep on hormone therapy--Consider EBRT boost instead of BT [132] Low and intermediate-risk cases: -Delay BT for at least 3-6 months For anxious patients, minimize the time of treatment (definitive) Definitive or adjuvant therapy (using endocrine): -Shorten BT fractionation schedules [136] Low-risk prostate cancer (Exclusive): -Postpone (8-12 weeks) Intermediate and high-risk prostate: -Postpone (8-12 weeks)

Low-risk prostate cancer (Exclusive): -Opt for surveillance Intermediate and high-risk prostate: -Opt for EBRT according to local facilities [134] Brachytherapy should be avoided as far as possible In centers where prostate BT is common: all (HDR) monotherapy cases (2 implants) should be converted to HDR boost (single implant 15 Gy in 1 fr) or switching to EBRT or starting of ADT -EBRT that are due for HDR boosts (15 Gy in 1 fr) can be converted to 37.5 Gy/15 fractions, -For experienced centers, BT can be delivered using LDR [135] Temporarily defer certain specialized procedures (HDR-BT) [71] Gynecological Cervix locally advanced cases (excluding verified or doubtful patients with COVID-19 infection) [133] Positive COVID-19 patients: -Postpone up to 10-14 days -Increase dose by 5 Gy / week deferent (consider OAR constraints) -Keep on BT boost with PPE precautions Negative COVID-19 patients: -Finalize treatment within 7-8 weeks [132] Chemotherapy/RT + BT ≤ 8 weeks [136] Boost: Continue for locally advanced case [134] When that is not feasible EBRT boost should be considered.

Adding approx. 5 Gy per week for each week of BT delay beyond seven weeks, respecting (OARs) tolerance doses [135] -Reducing the number of applications by delivering multiple fractions with each application -Using higher dose/fr (fewer fraction number) considering the indications (e.g., 3 × 8 Gy or 4 × 7 Gy) [137] [138] [139] [140] Adjuvant treatment: 9 Gy / 2 frs over 2 weeks, over conventional 7 Gy / 3-4 frs or 6 Gy / 5 frs [63] 9 Gy × 2 frs weekly (in patients with low volume disease post-RT and in whom inferior local control) [139] Stages IB3, IIA2-IIIC2, and early IVA: Intracavitary HDR brachytherapy 3 frs Stages IA1, IA2, IB1, IB2, IIA1: Vault brachytherapy 12 Gy/2 frs [33] For centers with single brachytherapy operating: postpone at least 24 days or until the infection is resolved Reduced number of fractions: 24 Gy/3 frs or 28 Gy/4 frs HDR ICBT: 7 Gy/4 frs at 1 week apart or 2 frs per day separated by a 6h interval For patients >70 yrs, significant comorbidities, small tumors, or responding well to RT: -Shortened schedule (9 Gy /2 frs at 1 week apart) -Brachytherapy for cervical cancer (stage IB1, IIIB) [138] Advanced cervical cancer: temporarily defer interstitial brachytherapy [71] Uterine -Postpone BT but no more than 12 weeks after surgery [136] Endometrial -Standard treatment (preferably three frs) [133] Inoperable definitive positive COVID-19 symptomatic patients: -Hold on RT for 10-14 days -Start BT after recovery [132] High-risk cases: -Postpone boost (8-12 weeks) -Opt EBRT according to local facilities [134] Interstitial BT for definitive COVID-19+ cases: -Delay treatment up to 10-14 days after recovery -Increase BT dose by 5 Gy / week deferent [132] Intermediate risk endometrial cancer (Exclusive): Postpone (8-12 weeks) or opt for surveillance [134] Postop vaginal cuff cases: -Postpone BT up to 8-9 weeks after surgery -Postpone BT boost by 2-3 weeks after RT [132] J o u r n a l P r e -p r o o f Patients who should start VVB: 7 Gy/3 frs (depth of 0.5 cm) with an interval spacing of 14 days between the fractions Stage II endometrial cancer with poor prognostic factors (if invasion > 50% of the myometrium, G3), and for stage I high-risk endometrial cancer: Adjuvant RT and brachytherapy [138] Vaginal Stage I: -Postpone BT up to 1 to 6 months for patients with significant comorbidities Advanced stage [138] Upper and lower vagina [33] Early vaginal cancer (stage I, < 5 mm of invasion) with significant comorbidities: postpone brachytherapy by 1 to 2 months For advanced stage: CRT followed by vaginal brachytherapy (7 Gy/3frs) Brachytherapy without any delay (curative treatment): stage I, < 5 mm of invasion, locally advanced stage [138] Vulvar low priority and only be carried out when operation theatre capacity allows it [135] Vulva: radical, adjuvant and palliative [33] Sarcoma Postpone BT boost until pandemic solves.

For COVID-19+ patients during RT, continue EBRT rather than brachytherapy boost [132] Soft-tissue sarcoma: -BT alone (HDR instead of LDR with iridium-192 wires) rather than 60-66 Gy / 1 . 8-2 Gy/ fr adjuvant EBRT [133] Pediatrics BT can be employed in specialized centers, especially for rhabdomyosarcoma [135] Pediatrics indication: To be discussed on an individual basis [134] Skin Non-melanoma skin cancers: -Use BT with fewer fractions, especially in inoperable patients [133] Thermoplastic mask with/without an intraoral device -Mask-on policy by fitting the thermoplastic mask to the patient after wearing a personal protective mask and cutting the end of a tongue depressor -to use an open-faced thermoplastic mask and place a nonstick barrier between it and a surgical mask

Italy [178] Mouthpiece-assisted head and shoulder thermoplastics masks during all positioning and setup process

The patient was asked to wear one surgical mask (or a second mask if the patient has tracheostomy) during the positioning steps. The thermoplastic mask was used after the setup confirmation.

-All treatment was done by VMAT technique and image-guidance. USA [179] SRS with frame-based immobilization SRS with mask-based treatment CBCT -Daily image guidance using CBCT to help assess the development of infiltrates in asymptomatic patients USA, France, China, Spain, the UK [74] CBCT IGRT (CT on rail, or CBCT) before the first fraction of the treatment France [148] Spirometry for respiratory gating -4D scanner imaging and daily CBCT-based positioning

Italy [184] CBCT -Daily image guidance using CBCT USA [14] Daily CBCT imaging -Weekly CBCT imaging or orthogonal films, especially when motion is minimal (brain lesions).

Breast, prostate, gynecologic USA [136] Brachytherapy: a) General anesthesia for implantations a) Procedural sedation and analgesia (PSA): -neuraxial analgesia (epidural, spinal, or combined spinal-epidural anesthesia; CSE) -pudendal nerve block

A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients

Radiology Perspective of Coronavirus Disease 2019 (COVID-19): Lessons From Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome

Novel Corona Virus Update

Radiation Protection in the Design of Radiotherapy Facilities

Radiotherapy workflow and protection procedures during the Coronavirus Disease 2019 (COVID-19) outbreak: Experience of the Hubei Cancer Hospital in Wuhan, China

Recommendations for radiotherapy during the novel coronavirus pandemic

Coronavirus disease 2019 (COVID-19): Cancer care during the pandemic

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Cancer and COVID-19: what do we really know?

Caring for cancer patients in the Covid pandemic: choosing between the devil and deep sea

Disease Site-Specific Guidelines for Curative Radiation Treatment During 'Limited Surgery' and 'Hospital Avoidance': A Radiation Oncology Perspective From the Epicenter of COVID-19 Pandemic

An Integrated Program in a Pandemic: Johns Hopkins Radiation Oncology Department

Clinical considerations for the management of cancer patients in the mitigation stage of the COVID-19 pandemic

Effect of COVID-19 pandemic on practice in european radiation oncology centers

Cancer or COVID-19? A Review of Guidelines for Safe Cancer Care in the Wake of the Pandemic

A national survey onradiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: present changes and future perspectives

Cancer care and COVID-19: tailoring recommendations for the African radiation oncology context

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Introduction: The significance of radiobiology and radiotherapy for cancer treatment

Radiation for Glioblastoma in the Era of COVID-19: Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk

First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments

COVID-19: Global radiation oncology's targeted response for pandemic preparedness

How to create a No fly zone: a Northern Italy experience

Coronavirus disease 2019 pandemic and its implications on triaging patients with brain tumors for surgery, radiotherapy, and chemotherapy

Neuro-oncology treatment guidance during COVID-19 pandemic

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk

Radiotherapeutic management of brain tumours during the COVID-19 pandemic

Radiation oncology in times of COVID-2019: A review article for those in the eye of the storm -An Indian perspective

Radiotherapy and COVID-19 pandemic-a review of the current recommendations

Should cancer treatment be continued during the COVID-19 pandemic? A single Egyptian institution experience

ISNO Position Statement on Treatment Guidance in Neuro-oncology During Pandemics

Impact of COVID-19 pandemic on a daily-based outpatient treatment routine: experience of a radiotherapy department of a tertiary public/university hospital in Brazil

The impact of Coronavirus (COVID-19) on head and neck cancer patients' care

Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement

Radiotherapy in the era of COVID-19

Head and neck cancer and COVID-19

Managing locally advanced adenoid cystic carcinoma of the head and neck during the COVID-19 pandemic crisis: Is this the right time for particle therapy?

Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach

Ocular oncology practice guidelines during COVID-19 pandemic-An expert consensus

Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic

Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID era

What is the best treatment option for head and neck cancers in COVID-19 pandemic? A rapid review

COVID-19: An advisory for a radiation oncology department pertinent to the multidisciplinary team

Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial

Rapid Adaptation of Breast Radiotherapy Utilization during the COVID-19 Pandemic at a Large Academic Cancer Centre in Canada

New policy and regulation for a Radiology-Oncology Center at the time of Covid-19 outbreak in Tehran-Iran

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

A practical approach to the management of breast cancer in the COVID-19 era and beyond

Diagnosis and locoregional treatment of patients with breast cancer during the COVID-19 pandemic

International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19

Organization of a radiotherapy service during the COVID-19 epidemic: Experience of Regional

The Impact of COVID-19 on Radiation Oncology and Cancer Care: A Perspective from the Cancer Belt Region of India

Multidisciplinary approach to COVID-19 and cancer: consensus from scientific societies in Argentina

Emergency guidelines for pre-operative breast radiotherapy during the COVID-19 pandemic

Breast Cancer Management Guidelines During COVID-19 Pandemic

Management changes for patients with endocrine-related cancers in the COVID-19 pandemic

Implementing continued radiation therapy for cancer management in low resource countries during and after the COVID-19 crisis

Maintaining breast cancer care in the face of COVID-19

Management of breast cancer during COVID-19 pandemic in Morocco

Management policies of breast cancer surgery, chemotherapy and radiotherapy during COVID-19 outbreak in Iran

Implementation of breast cancer continuum of care in low-and middle-income countries during the COVID-19 pandemic

Proposals for the modification of diagnostics and combination treatment of breast cancer during the COVID-19 pandemic

The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience

GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain

Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Outbreak Response Taskforce

Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2

Bracing for impact with new 4R's in the COVID-19 pandemic -A provincial thoracic radiation oncology consensus

Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak

Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic

Single-Fraction Stereotactic Body Radiotherapy: A Paradigm During the COVID-19 Pandemic and Beyond?

Lung Cancer Management in COVID-19 Pandemic

Implications of COVID-19 pandemic on lung cancer management: A multidisciplinary perspective

Management of Lung Cancer During the COVID-19 Pandemic

Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group

Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change

Treatment Guidance for Patients With Lung Cancer During the Coronavirus

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic

Considerations for the Treatment of Oesophageal Cancer With Radiotherapy During the COVID-19 Pandemic

Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19

Considerations for treatment of oesophagogastric cancers within the United Kingdom during the COVID-19 pandemic

Considerations for Treatment of Pancreatic Cancer within the United Kingdom During the COVID-19 Pandemic

Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Challenges and Consequences of COVID-19 in the Management of Anorectal Cancer: Coming Together Through Social Distancing

Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit

Lower GI response to the COVID-19 outbreak

Radiotherapy management of rectal cancer in the backdrop of the COVID pandemic

Recommendations on Management of Locally Advanced Rectal Cancer During the COVID-19 Pandemic: an Iranian Consensus

Treatment approach in locally advanced rectal cancer during coronavirus (COVID-19) pandemic: long course or short course?

Guidance for management of urothelial cancer during COVID-19 pandemic

Prostate Cancer Radiotherapy Recommendations in Response to COVID-19

A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association

Guidance for treatment of uro-oncology patients during COVID-19 pandemic

Increased number of prostate cancer patients selecting high dose-rate interstitial brachytherapy during the COVID-19 pandemic

Management of prostate cancer patients during COVID-19 pandemic

Prostate cancer management challenges due to COVID-19 in countries with low-to-middleincome economies: A radiation oncology perspective

Prostate Ultrahypofractionation -Rising to Challenges Presents Opportunities in the COVID-19 Era

Rapid implementation of extreme hypofractionation protocols in prostate cancer using RapidPlan(R) in response to COVID-19

Guidance for radiotherapy for gynaecological cancer and COVID-19

COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations

Management of cervical cancer during the corona virus disease-19 (COVID-19) era

Recommendations for gynecologic cancer care during the COVID-19 pandemic

Recommendations on management of gynecological malignancies during the COVID-19 pandemic: perspectives from Chinese gynecological oncologists

ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies

Gynecological cancers and the global COVID-19 pandemic

Personalizing vulvar cancer workflow in COVID-19 era: a proposal from Vul.Can MDT

Updated neoadjuvant/adjuvant/definitive radiotherapy guidelines for the management of newly diagnosed soft-tissue and bone sarcoma

A rapid review of evidence and recommendations from the SIOPE radiation oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises

Prioritisation of paediatric and TYA patients (with paediatric-type tumours) for radiotherapy during the COVID-19 pandemic

The COVID-19 pandemic: A rapid global response for children with cancer from SIOP

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance

Management of primary skin cancer during a pandemic: Multidisciplinary recommendations

Radiotherapy and Systemic Treatment for Non-melanoma Skin Cancer in the COVID-19 Pandemic

Radiotherapy for melanoma in COVID-19 pandemic

Consensus Guidelines for the Management of Melanoma during the COVID-19 Pandemic: Surgery, Systemic Anti-cancer Therapy, Radiotherapy and Follow-up

Skin cancer triage and management during COVID-19 pandemic

Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper

Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care

Tackling brain metastases from lung cancer during the COVID-19 pandemic

Malignant spinal cord compression (MSCC) presentation before and during Covid-19

Palliative Radiation Therapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefits

Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic

Brachytherapy during the COVID-19-Lessons from Iran

BRACHYTHERAPY ISSUES AND PRIORITIES IN THE CONTEXT OF COVID-19 OUTBREAK

Brachytherapy practice during the COVID-19 pandemic: a review on the practice changes

COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation

Brachytherapy in cervical cancer radiotherapy during COVID-19 pandemic crisis: problems and prospects

COVID-19, Brachytherapy, and Gynecologic Cancers: a Moroccan Experience

Recapitulating intracavitary brachytherapy in cervical cancer patients during the COVID-19 pandemic: a viewpoint

COVID-19 and Gynecological Cancers: A Summary of International Recommendations

A Canadian Response to the Coronavirus Disease 2019 (COVID-19) Pandemic: Is There a Silver Lining for Radiation Oncology Patients?

Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal

Comment on "Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiotherapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement

The Impact of the Acute Phase of COVID-19 on Radiotherapy Demand in South East Wales

Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer

Adapting Radiation Therapy Treatments for Patients with Breast Cancer During the COVID-19 Pandemic: Hypo-Fractionation and Accelerated Partial Breast Irradiation to Address World Health Organization Recommendations

Radiotherapy department reorganization during the COVD-19 outbreak: keys to securing staff and patients during the first weeks of the crisis and impact on radiotherapy practice from a single institution experience

Postlockdown management of oncological priorities and postponed radiation therapy following the COVID-19 pandemic: Experience of the institut curie

COVID-19 Pandemic as an Opportunity for the Radiotherapy Department

Zambia's National Cancer Centre response to the COVID-19 pandemic-an opportunity for improved care

Accelerated Adaptation of Ultrahypofractionated Radiation Therapy for Breast Cancer at the Time of the COVID-19 Pandemic

Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?

Thoracic radiation therapy during COVID-19: provisional guidelines from a comprehensive cancer center within a pandemic epicenter

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

SABR-BRIDGE: Stereotactic ABlative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts During the COVID-19 Pandemic

Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?

Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group

Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?

Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position

Liver Stereotactic Ablative Radiotherapy: an Effective and Feasible Alternative to Surgery during the COVID-19 Pandemic

Treatment approach in locally advanced rectal cancer during coronavirus (COVID-19) pandemic: long course or short course?

Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center

Caring for Patients with Rectal Cancer During the COVID-19 Pandemic

Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice

Radiotherapy and COVID-19: Practical recommendations from iran

Managing the COVID-19 Pandemic as a National Radiation Oncology Centre in Singapore

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

COVID-19 and gynecological cancers: A Moroccan point-of-view

Should we embrace hypofractionated radiotherapy for cervical cancer? A technical note on management during the COVID-19 pandemic

Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of Patients

Hypofractionated radiotherapy in patients with non-melanoma skin cancer in the post COVID-19 era: Time to reconsider its role for most patients

Dexamethasone for the prevention of a pain flare after palliative radiotherapy for painful bone metastases: the multicenter double-blind placebo-controlled three-armed randomized Dutch DEXA study

Palliative Radiotherapy for Oncologic Emergencies in the setting of COVID-19: Approaches to Balancing Risks and Benefits

Comments on the publication by Yerramilli et al titled "Palliative Radiotherapy for Oncologic emergencies in the setting of COVID-19: Approaches to Balancing Risks and Benefits

Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere

Practical Challenges of Mask-to-Mask Encounters with Patients with Head and Neck Cancers amid the Coronavirus Disease 2019 Pandemic

Head and neck cancer radiotherapy amid COVID-19 pandemic

Clinical Considerations in Neurosurgical Radiosurgery in the Time of COVID-19

Concerns for activated breathing control (ABC) with breast cancer in the era of COVID-19: Maximizing infection control while minimizing heart dose

A rapid transition to voluntary breath hold from device-assisted moderate deep inspiration breath hold for patients receiving breast radiotherapy during the COVID-19 pandemic

Covert Covid-19: CBCT Lung Changes in An Asymptomatic Patient Receiving Radiotherapy

Practice considerations for proton beam radiotherapy of uveal melanoma during the COVID-19 pandemic: PTCOG Ocular experience

Effectiveness of CBCT imaging during radiotherapy for the detection of initial COVID-19 lung disease

A systematic review and meta-analysis of cancer patients affected by a novel coronavirus

DIrectory of RAdiotherapy Centres (DIRAC

Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic

COVID-19 Recommendations for Patients with Cancer: The

Adapting to the contemporary normal in cancer management and workflow during COVID-19 situation in the Philippines: Multi-cancer center collaborative approach

Radiotherapy during COVID-19 pandemic. How to create a No fly zone: a Northern Italy experience

How we treat patients with brain tumour during the COVID-19 pandemic

COVID-19 and radiotherapy: potential new strategies for patients management with hypofractionation and telemedicine

A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low-and middle-income countries

Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement

A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic

Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic

Bladder cancer during the COVID-19 pandemic: the calm before the storm?

COVID-19 and gynecological cancer: a review of the published guidelines

Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer

Adapting Management of Sarcomas in COVID-19: An Evidence-Based Review

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Nationwide Trends in Heart-Sparing Techniques Utilized in Radiation Therapy for Breast Cancer

Cardiac-sparing radiation therapy using positioning breast shell for patients with leftsided breast cancer who are ineligible for breath-hold techniques

Role of belly board device in the age of intensity modulated radiotherapy for pelvic irradiation

Characterization of Respiration-Induced Motion in Prone Versus Supine Patient Positioning for Thoracic Radiation Therapy

STAFF AND PATIENTS' PROTECTION IN RADIATION ONCOLOGY DEPARTMENTS DURING COVID-19 PANDEMIC

Clinical guide for the management of cancerpatientsduring the coronavirus pandemic

COVID-19: hypofractionation in the Radiation Oncology Department during the 'state of alarm': first 100 patients in a private hospital in Spain

Hypofractionated Radiotherapy in Oesophageal Cancer for Patients Unfit for Systemic Therapy: A Retrospective Single-Centre Analysis

De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era

Adapting care for older cancer patients during the COVID-19 pandemic

Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists

Extent of prior lung irradiation and mortality in COVID-19 patients with a cancer history

Locally advanced): cCRT Locoregional advanced hypopharyngeal: cCRT (fit patients) Nasopharynx (stage II-IV): NACT followed by CRT (IMRT) Early glottic cancer: RT Oral cavity (early resectable) and high-risk factors such as margin positivity and perinodal extension: cCRT (definite overall survival benefit) Nasopharynx (stage I): RT [48] Head-and-neck: RT as the main treatment [37] Hypo-F CRT for head and cancer

Gy/30 frs rather than standard fractionation 70 Gy/35 frs Locally advanced laryngeal cancer: 67.2 Gy / 28 frs Hypo-F RT alone: 60 Gy/25frs (T1-T3 N0-N2c HPV+ and T1-T2 N0 HPV-) Oropharyngeal patients: 60 Gy/30 frs Hypo-F accelerated RT: 64 Gy / 25 frs Locally advanced disease: IMRT (55 Gy/20 frs

Urgent cases: pain due to bone metastases, cord compression, SVCO, and tumor bleeding: 5-8 Gy/1 fr (single fraction) Hypo-F RT and single fraction palliative RT [63] Treatment is limited to function-or life-threatening situations (e.g., spinal cord compression) The shortest possible course (e.g., single-fraction treatment for bone pain [128] Palliative RT: spinal cord compression, uncontrolled bleeding from fungating tumors

Postop for a pathological fracture Palliative treatment of bleeding/fungating inoperable breast mass, spinal cord compression, and symptomatic brain metastases [67] Single or two weekly fractions for palliative thoracic RT [78] -Single-fraction for bone metastases and spinal cord compression: 8-24 Gy / 1 fr -Airway obstruction:17 Gy / 2 frs [79] No spinal compression Bone Mets, fracture/spinal compression

Palliative RT in a single 8 Gy fr for symptomatic disease (local or metastatic

Arteriovenous malformations: SRS or Hypo-F SRS Brain metastases: -For solitary/limited brain met with good DS-GPA (single fraction frameless SRS) -Hypo-F RT:30-35 Gy / 5-6 frs -For multiple brain metastases/whole-Brain: Hypo-F RT (20 Gy / 5frs) Spinal cord compression: Hypo-F RT

Palliative/temporary control of vulvar cancer: -Long course: 30 Gy/10 frs -Short course: 16 Gy/4 frs or 20 Gy/5 frs (symptomatic patients) [113] Palliative treatment of head and neck malignancies

20 Gy / 5 frs given daily -Single fraction of 8Gy SVCO: -20 Gy / 5 daily frs -8-10 Gy in a single fraction Painful bone metastases: 8 Gy single fraction [33] Thoracic patients with oligometastatic disease Symptomatic metastases (pain, obstruction, or bleeding) palliative short course Hypo-F RT: 8 Gy/10 Gy or SBRT [80] Cord compression or bony metastases: 20 Gy/5 frs or 8-10 Gy/1fr or 30 Gy/10 frs for good prognosis Breast palliation: 6 Gy for 5 to 6 weeks Brain metastases: where appropriate: SRS; all others: 20 Gy/5 frs or 12 Gy/2frs (daily) [69] Hypo-F RT: -Bone metastasis: 6-8 cGy/1fr; 15 Gy/3 frs; 20 Gy/5 frs to a small radiation field -Brain metastasis: 20 Gy/5frs [35] Palliative RT for melanoma: COVID-19 negative patients (No delay) COVID-19 positive patients: In case of pain or dedicated COVID-19 positive RT pathways [126] Brain metastases from lung cancer (whole brain RT) Short course Hypo-F RT: 20 Gy/5 frs; 30 Gy/10 frs (patients with better survival outcomes); 12 Gy /2 frs (once a week) in patients with poor PS Hypo-F boost of 10 -15 Gy after WBRT Single fraction SRS as an alternative to surgery (oligo-metastases and controlled extracranial disease

Keloids (Exclusive) Omit BT and consider options

Palliative BT should be avoided and replaced by Hypo-F EBRT

HDR: high-dose-rate, LDR: low-dose-rate, SCC: squamous cell carcinoma, PPE: personal protective equipment, IORT, intra-operative radiotherapy

The authors would like to thank physicians, medical physicists, radiotherapy technicians, and all the nursing team of ????, for staying on the front line during this crisis. The authors would like to acknowledge and express their gratitude to numerous radio-oncologist colleagues for their valuable contributions to distribute this survey. We are also grateful to all physicians and caregivers worldwide who are doing their best to treat cancer patients during the COVID-19 pandemic.

J o u r n a l P r e -p r o o f

b) MRI guidance for IGBT of gynecologic malignancies -moderate sedation (midazolam and fentanyl) -local analgesia (with topical/mucosal lidocaine and/or tissue infiltration) b) Confined MR-based planning:-Just CT-based planning for local cervical cancer patients with limited vaginal involvement (T1b-2a stages) -MRI-based planning for the extra-cervical spread of malignancies (T2b-T4a stages) and choose one of these strategies: 1) Inpatient strategy: MRI-based BT with the applicator in situ for two treatment fractions 2) Outpatient strategy: have a pre-BT MRI and incorporated it with CT performed at implantation time 3) Using a smit sleeve placed at first implant time for CT-based planning with subsequent MR fusion 4) Using 'cognitive fusion' and contouring on a CT with the applicator in place referring to a pre-BT MRI Breast, prostate, gynecologic, head and neck, skin Iran [133] General anesthesia for implantations -Give priority to local or spinal anesthesia for applicator insertion -Balloon or catheter-based APBI is preferred to be inserted intraoperatively

USA [132] India [135, 139] -